A year after debuting with $500M, Bob Nelsen's Really Big Neuroscience Company raises a really not-as-big Series B

Max Gelman

Senior Editor

In putting together another nine-figure financing round, ARCH-backed Neumora is attempting to straddle the very fine line between hype and surreptitiousness.

Last October, the biotech emerged from stealth with a whopping $500 million in cash reserves, a Big Pharma collaboration with Amgen and a big vision to remake the way researchers investigate new psychiatric and neuroscience drugs. Neumora’s code name before its debut was simply “Really Big Neuroscience Company,” not-so-subtly hinting at investors’ aspirations.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

A year after debuting with $500M, Bob Nelsen's Really Big Neuroscience Company raises a really not-as-big Series B

Max Gelman

Senior Editor

Unlock this article instantly by becoming a free subscriber.

The next generation of AI biotechs is here. Can they deliver on the hype?

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

CHMP recommends eight new drug approvals, six label expansions

A year af­ter de­but­ing with $500M, Bob Nelsen's Re­al­ly Big Neu­ro­science Com­pa­ny rais­es a re­al­ly not-as-big Se­ries B

Max Gelman

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Bris­tol My­ers to shut­ter Bay Area cell ther­a­py R&D fa­cil­i­ty as it elim­i­nates jobs and costs

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

CHMP rec­om­mends eight new drug ap­provals, six la­bel ex­pan­sions

A year after debuting with $500M, Bob Nelsen's Really Big Neuroscience Company raises a really not-as-big Series B

The next generation of AI biotechs is here. Can they deliver on the hype?

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

CHMP recommends eight new drug approvals, six label expansions